We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Agreed, all looks a bit dodgy. If you get an honest answer I'll be amazed. See some clown sold out way below last night's price this am....
Virtually no premium to yesterdas close for a rapidly growing profit making company? I also noticed in todays interims there is no mention of the Asian market where they were rolling out across Chinese hospitals from 21 grossing $3.3million to 169 hospitals. If you extrapolate that then that should equate to roughly $26million revenue of course it never works like that but surely there must be a significant increase in revenue from China and if not then why not and why leave a massive market out of the interims? All seems a bit fishy to me that they would let the company go so cheaply whilst at the same time missing out a huge area they operate in from the interims. Would they have done this to make the deal appear better than it is? I've emailed the company for answers but wont hold my breath.
It's fairly illiquid. Try breaking your order into smaller chunks.
I seem to have spent 24 hours trying to buy this share, why is it so tough, why are the prices above those of the market makers etc etc?
@ 218p way above the advertised ask of 216p. How long until people see the potential here?
I have high hopes for this company. The growth potential is great and with their continued expansion in Asia, the Americas (and the rest of the world to be fair) I think the SP going forward will start to motor when the final results for 2015 are released.
for 2015 forecast to be double that of 2014 and a fund - Health Invest has got over 3%. A few large buys this AM too.
Seymour Pierce continues to see medical technology group Lifeline Scientific making strong progress on sales, product development and geographical expansion. The broker has a 260p target price on Lifeline and a “buy” recommendation. “The phasing of R&D expenditure means the company is ahead of our interim earnings expectations, while we anticipate total investment for the full-year to be in line with our existing assumptions,” Seymour Pierce notes. It points to Lifeline’s low valuation of 12.6 times estimated 2012 earnings, which compares with 16.8 for peer Advanced Medical Solutions and 17.4 for Surgical Innovations.